试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-10-18
A Study to Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids
编号:NCT03240523登记状态:提前终止企业 / 申办者:Bayer
药物 / 成分:Vilaprisan (BAY1002670)
登记的停止原因(原文):Due to a change in the development program, the study was closed prematurely.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-10-18
Paracetamol And Ibuprofen/Indomethacin in Closing Patent Ductus Arteriosus
编号:NCT03648437登记状态:提前终止企业 / 申办者:University of Oulu
药物 / 成分:Paracetamol 10Mg/mL、0.45% Sodium Chloride、Ibuprofen、Indomethacin
登记的停止原因(原文):The PDA patients have vanished. The last recruitment took place in 2022. In the joint discussion of the principal researchers, it was concluded that PDA patients no longer have to be treated in Finland and the study was terminated.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-10-18
Intratumoral Tilsotolimod, a TLR-9 Agonist, Together With Intratumoral Ipilimumab and Intravenous Nivolumab in Patients With Advanced Cancers
编号:NCT04270864登记状态:提前终止企业 / 申办者:Gustave Roussy, Cancer Campus, Grand Paris
药物 / 成分:Ipilimumab、Nivolumab、Tilsotolimod
登记的停止原因(原文):The part A of the trial has been completed according to the protocol. The part B has not been opened because of unfeasibility (experimental products not yet available).
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-10-18
IDH1 Inhibitor AB-218 in Patients With Advanced IDH1 Mutant Cholangiocarcinoma and Other Solid Tumor
编号:NCT05814536登记状态:提前终止企业 / 申办者:AnHeart Therapeutics Inc.
药物 / 成分:AB-218 capsule
登记的停止原因(原文):Sponsor adjusted the study strategy
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-10-18
Oxidative Stress and Circulating Nuclear DNA (cfDNA) in Acute Kidney Injury and Continuous Renal Replacement Therapies.
编号:NCT06646328登记状态:提前终止企业 / 申办者:Fernando Sanchez
药物 / 成分:Central venous access、Pump-assisted circuit、Heparin sodium、Regional citrate anticoagulation
登记的停止原因(原文):Enrollment slower than anticipated and interrupted by COVID-19 pandemic
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-10-17
Inhaled Nitric Oxide and Neuroprotection in Premature Infants
编号:NCT00515281登记状态:提前终止企业 / 申办者:University of Chicago
药物 / 成分:inhaled nitric oxide、oxygen
登记的停止原因(原文):The pace of patient enrolledment forced recruitment to stop after 273 patients.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-10-17
CPI-613 in Treating Patients With Myelodysplastic Syndromes Who Failed Previous Therapy
编号:NCT01902381登记状态:提前终止企业 / 申办者:Wake Forest University Health Sciences
药物 / 成分:6,8-bis(benzylthio)octanoic acid
登记的停止原因(原文):Drug sponsor suspended study prematurely then study was terminated. Expected enrollment was not met.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-10-17
SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First Complete Remission
编号:NCT02270463登记状态:提前终止企业 / 申办者:Stemline Therapeutics, Inc.
药物 / 成分:Tagraxofusp-erzs
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-10-17
Effects of Probiotics on Symptoms of Depression
编号:NCT03277586登记状态:提前终止企业 / 申办者:Dr. Roumen Milev
药物 / 成分:Probio'Stick、Placebo
登记的停止原因(原文):COVID-19
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-10-17
PK and Dose Escalation and Expansion Study of DST-2970
编号:NCT04291664登记状态:提前终止企业 / 申办者:DisperSol Technologies, LLC
药物 / 成分:Abiraterone Acetate、Prednisone 5Mg Tab、DST-2970 (Abiraterone)
登记的停止原因(原文):Dose escalation portion of the study completed, one expansion cohort was eliminated due to change in standard of care, and the second cohort was not enrolled based on future development considerations.
查看官方原始记录 ↗